Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Novartis' blood disorder drug gets FDA approval for expanded use

November 16, 2018 11:11 PM
134 0

(Reuters) - Novartis AG said on Friday the U.S. Food and Drug Administration expanded the use of its low platelets drug to treat patients with a rare, genetic blood disorder.

The drug, Promacta, received the green light as a combination with standard immunosuppressive therapy to treat patients two years and older suffering from treatment-resistant severe aplastic anemia (SAA).

Read more

Share in social networks:

Comments - 0